The CD4+/CD8+ ratio of renal cell carcinoma patients treated with vinblastine in combination with human IFN-α was higher compared to those that had been treated with vinblastine alone [35]. This evidence concerns the gene CD4 and hereditary clear cell renal cell carcinoma.